Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation

Oncologist

Volumn 5, Issue SUPPL. 1, 2000, Pages 45-50

  Verheul, H M W ^b   Hoekman, K ^b   Jorna, A S ^b   Smit, E F ^a   Pinedo, H M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Ascites; Pleural effusion; Vascular endothelial growth factor

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ASCITES; CELL CULTURE; CELL PROLIFERATION; CLINICAL FEATURE; CONFERENCE PAPER; DRUG MECHANISM; HUMAN; HUMAN CELL; PLEURA EFFUSION; PRIORITY JOURNAL;

EID: 0033996776     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-suppl_1-45     Document Type: Conference Paper

References (39)

1. Rustgi AK, Rotolo FS, Peete WP et al. Successful management of late-onset primary lymphatic hypoplasia. Surgery 1985;97:714-720.
2. Reshad K, Inui K, Takeuchi Y et al. Treatment of malignant pleural effusion. Chest 1985;88:393-397.
3. Li KW, Wong WS. Double valve Denver peritoneal venous shunt used in ovarian malignant ascites. A case report. Chin Med J (Engl) 1989;102:300-302.
4. Schumacher DL, Saclarides TJ, Staren ED. Peritoneovenous shunts for palliation of the patient with malignant ascites. Ann Surg Oncol 1994;1:378-381.
5. Lipsky MS, Sternbach MR. Evaluation and initial management of patients with ascites. Am Fam Physician 1996;54:1327-1333.
6. Alberts WM, Salem AJ, Solomon DA et al. Hepatic hydrothorax. Cause and management. Arch Intern Med 1991;151:2383-2388.
7. Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J 1997;10:1907-1913.
8. Senger DR, Perruzzi CA, Feder J et al. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629-5632.
9. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-858.
10. Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312.
11. Neufeld G, Cohen T, Gengrinovitch S et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
12. Vaisman N, Gospodarowicz D, Neufeld G. Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 1990;265:19461-19466.
13. De Vries C, Escobedo JA, Ueno H et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-991.
14. Terman BI, Dougher-Vermazen M, Carrion ME et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187:1579-1586.
15. Waltenberger J, Claesson-Welsh L, Siegbahn A et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995.
16. Shalaby F, Rossant J, Yamaguchi TP et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-66.
17. Millauer B, Shawver LK, Plate KH et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-579.
18. Nagy JA, Masse EM, Herzberg KT et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;55:360-368.
19. Luo JC, Yamaguchi S, Shinkai A et al. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res 1998;58:2652-2660.
20. Yano S, Shinohara H, Kuniyasu H et al. Formation of pleural effusion by human lung adenocarcinoma directly correlates with expression of VEGF/VPF. Proc Am Assoc Cancer Res 1999;40:227a.
21. Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 1998;58:2594-2600.
22. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-1256.
23. Zebrowski BK, Liu W, Ramirez K et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6:373-378.
24. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999;54:707-710.
25. Cheng D, Rodriguez RM, Perkett EA et al. Vascular endothelial growth factor in pleural fluid. Chest 1999;116:760-765.
26. Van Hinsbergh VWM, Draijer R. Culture and characterization of human endothelial cells. In: Shaw AJ, ed. Epithelial Cell Culture; A Practical Approach. New York, NY: Oxford University Press, 1996:87-110.
27. Westermann AM, Havik E, Postma FR et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 1998;9:437-442.
28. Gawrychowski K, Skopinska-Rózewska E, Barcz E et al. Angiogenic activity and interleukin-8 content of human ovarian cancer ascites. Eur J Gynaecol Oncol 1998;19:262-264.
29. Harley RA. Pathology of pleural infections. Semin Respir Infect 1988;3:291-297.
30. Woodring JH, Vandiviere HM, Fried AM et al. Update: the radiographic features of pulmonary tuberculosis. AJR Am J Roentgenol 1986;146:497-506.
31. Hatipoglu ON, Osma E, Manisali M et al. High resolution computed tomographic findings in pulmonary tuberculosis. Thorax 1996;51:397-402.
32. Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997;57:765-772.
33. Esser S, Wolburg K, Wolburg H et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998;140:947-959.
34. Dvorak HF, Nagy JA, Berse B et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci 1992;667:101-111.
35. Brown LF, Olbricht SM, Berse B et al. Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J Immunol 1995;154:2801-2807.
36. Hazelton D, Nicosia RF, Nicosia SV. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 1999;5:823-829.
37. Verheul HMW, Hoekman K, Lupu F. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000;6:166-171.
38. Fava RA, Olsen NJ, Spencer-Green G et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-346.
39. Wang W, Merrill MJ, Borchardt RT. Vascular endothelial growth factor affects permeability of brain microvessel endothelial cells in vitro. Am J Physiol 1996;271:C1973-C1980.